Business
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of
About this update from Entrada Therapeutics, Inc.
[{"type":"text","content":"New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug applications to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 and for ENTR-701 targeting myotonic dystrophy type 1 in 2023 BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today presented updates to its two lead programs at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics Conference. The company announced new non-human primate (NHP) data demonstrating durability of response through 12 weeks for ENTR-601-44, an EEV-conjugated phosphorodiamidate morpholino oligomer (PMO) for the potential treatment of people with Duchenne muscular dystrophy (DMD) who are exon 44 skipping amenable. Entrada also announced its second clinical candidate, ENTR-701, an EEV-PMO that the company is developing as a potential allele-specific treatment for people living with myotonic dystrophy type 1 (DM1). “We are proud to present new data at TIDES USA for our lead clinical candidate, ENTR-601-44 for Duchenne muscular dystrophy, and to announce our clinical candidate for myotonic dystrophy type 1 as we continue to expand our pipeline of EEV therapeutics,” said Natarajan Sethuraman, PhD, Chief Scientific Officer of Entrada. “To date, we have generated robust in vitro and in vivo preclinical data supporting the advancement of our DMD and DM1 programs. These encouraging data reinforce the potential of our EEV therapeutic candidates to engage previously inaccessible and undruggable disease-causing targets within cells, and we look forward to presenting additional data at upcoming scientific meetings.” The new data from a preclinical study evaluating ENTR-601-44 for the potential treatment of DMD, show robust exon 44 skipping in NHP biceps through 12 weeks following a single intravenous (IV) infusion, demonstrating durability of response (See Figure 1). These data build o...